Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -7.08% is 230% below its 5-year average of -2.15%, near the low end of its 5-year range (-7.54%–1.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 409.51% below its 12-month average of -1.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -7.08%.
RETURN ON EQUITY (ROE)
-7.08%
RETURN ON EQUITY (ROE) AVG TTM
-1.39%
RETURN ON EQUITY (ROE) AVG 3Y
-2.41%
RETURN ON EQUITY (ROE) AVG 5Y
-2.15%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-409.51%
CURRENT VS 3Y AVG
-193.13%
CURRENT VS 5Y AVG
-229.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.46%
median of 339 covered companies
CURRENT VS SECTOR MEDIAN
+75.13%
vs the sector median at left
Certara, Inc.
Market Cap
$1.57B
Return on Equity (ROE)
-7.08%
TTM Avg
-1.39%
3Y Avg
-2.41%
5Y Avg
-2.15%
Market Cap
$1.52B
Return on Equity (ROE)
27.24%
TTM Avg
-16.62%
3Y Avg
-27.07%
5Y Avg
-49.65%
Market Cap
$1.52B
Return on Equity (ROE)
-17.32%
TTM Avg
-19.51%
3Y Avg
-16.07%
5Y Avg
-12.58%
Market Cap
$1.51B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.65B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
Market Cap
$1.65B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
Market Cap
$1.46B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.43B
Return on Equity (ROE)
N/A
TTM Avg
36.18%
3Y Avg
36.18%
5Y Avg
36.18%
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Certara, Inc. (CERT) | $1.57B | -7.08% | -1.39% | -2.41% | -2.15% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 27.24% | -16.62% | -27.07% | -49.65% |
| GH Research PLC (GHRS)vs › | $1.52B | -17.32% | -19.51% | -16.07% | -12.58% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | -1058.20% | -465.87% | -348.95% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 17.72% | 5.08% | 0.03% | -3.88% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | 36.18% | 36.18% | 36.18% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 15.35% | -64.31% | -71.44% | -70.74% |
ROE
-7.1%
ROA
-4.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -7.08% |
| 2026-03-31 | -1.48% |
| 2025-12-31 | -0.15% |
| 2025-09-30 | 1.02% |
| 2025-06-30 | 0.75% |
| 2025-03-31 | -0.24% |
| 2024-12-31 | -1.14% |
| 2024-09-30 | -2.95% |
| 2024-06-30 | -7.54% |
| 2024-03-31 | -5.82% |
| 2023-12-31 | -5.29% |
| 2023-09-30 | -3.21% |
| 2023-06-30 | 1.75% |
| 2023-03-31 | 1.28% |
| 2022-12-31 | 1.36% |
| 2022-09-30 | -0.39% |
| 2022-06-30 | -0.94% |
| 2022-03-31 | -1.15% |
| 2021-12-31 | -1.27% |
| 2021-09-30 | -5.97% |
| 2021-06-30 | -6.59% |
| 2021-03-31 | -5.97% |
| 2020-12-31 | -6.01% |
| 2020-09-30 | -0.19% |
| 2020-06-30 | 0.12% |
| 2020-03-31 | -1.02% |
| 2019-12-31 | -1.81% |
